Impact of neoadjuvant chemotherapy with or without Zometa [zoledronic acid] on occult micrometastases and bone density in women with locally advanced breast cancer

Trial Profile

Impact of neoadjuvant chemotherapy with or without Zometa [zoledronic acid] on occult micrometastases and bone density in women with locally advanced breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Zoledronic acid (Primary) ; Antineoplastics; Docetaxel; Epirubicin; Trastuzumab
  • Indications Advanced breast cancer; Bone metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Results reported in Lancet Oncology.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top